Revolo Biotherapeutics announced it has activated clinical sites and opened enrollment in a Phase 2 clinical trial of its eosinophilic esophagitis therapy.
We applaud the efforts of Ms Ednan-Laperouse and Ms Turay and believe their concept of a single person responsible for the health and safety of the allergic community should be adopted here in the US.
Phase 3 trial in (EoE) to show a significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older